Sanuwave Health said it expects third-quarter revenue of $11.4 million to $11.6 million, below its previous expectations, blaming uncertainty around proposed reimbursement changes for some treatment ...

The quarter started slowly, and we simply could not make up the ground despite ending on a high note with September being the highest revenue month in Sanuwave history. That said, based on the ...

Sanuwave announces preliminary revenues of $11.4 million to $11.6 million for the third quarter ended September 30, 2025. This represents the ...

SANUWAVE Health Inc (SNWV) reports record quarterly revenue but adjusts annual guidance due to market disruptions and ...

Credit facility from J.P. Morgan consists of a four-year term loan of $23 million and a two-year $5 million revolving credit facility backed by ...

Detailed price information for Sanuwave Health Inc (SNWV-Q) from The Globe and Mail including charting and trades.

EDEN PRAIRIE, Minn., July 22, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (NASDAQ: SNWV), a leading provider of next-generation, FDA-approved wound care products , today announced, that Morgan ...

Insiders were net buyers of SANUWAVE Health, Inc.'s (NASDAQ:SNWV ) stock during the past year. That is, insiders bought more stock than they sold. While we would never suggest that investors should ...

Roth Capital Markets analyst Kyle Bauser reiterated a “Buy” rating and US$55.00 target price on Sanuwave Health ...

“These conferences allow us to highlight the significant growth opportunities inherent in our recent acquisition of Celularity’s UltraMIST® assets before different audiences of interested investors.

Soulstring Media Group points to record-setting Q3 revenues as a starting point for accelerating growth. Transformative acquisitions pave the way for robust 2021 Sentiment outside of SNWV is bullish.